Experimental antibody boosts chemo in ovarian cancer trial
NCT ID NCT05605535
First seen Apr 06, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This phase 2 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps control advanced ovarian, fallopian tube, or peritoneal cancer better than chemo alone. About 88 women with newly diagnosed stage III or IV disease will receive the combination or a placebo before and after surgery. The main goal is to see if the combination improves progression-free survival at 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amrita Institute of Medical Sciences
Kochi, Kerala, 682041, India
-
Himalaya Cancer Hospital and Research Institute
Vadodara, Gujarat, India
-
Institute of Medical Sciences, BHU
Varanasi, Uttar Pradesh, 221005, India
-
JIPMER
Puducherry, Puducherry, 605006, India
-
KLES Dr. Prabhakar Kore Hospital and Medical Research Centre
Belagavi, Karnataka, 590010, India
-
Kailash Cancer Hospital and Research Centre
Vadodara, Gujarat, India
-
King George Hospital
Visakhapatnam, Andhra Pradesh, India
-
King Georges Medical University
Lucknow, Uttar Pradesh, 226003, India
-
MNJ Cancer Hospital
Hyderabad, Telangana, 500004, India
-
Omega Hospitals
Visakhapatnam, Andhra Pradesh, 530040, India
-
Regional Cancer Centre, Medical College
Trivandrum, Kerala, 695011, India
-
Saveetha Medical College and Hospitals
Chennai, Tamil Nadu, 602105, India
-
Sri Ram Cancer Hospital
Jaipur, Rajasthan, 302022, India
-
Sri Ramchandra Medical Centre
Chennai, Tamil Nadu, India
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Oregovomab (an experimental antibody) plus chemotherapy (paclitaxel and carboplatin)
What this could lead to
If it works, this could lead to a new treatment option that helps control advanced ovarian cancer for longer before surgery.
What could go wrong
This is a mid-stage trial with only 88 participants, so results may not apply to everyone. The drug could cause side effects or not improve outcomes compared to chemo alone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.